G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Global Neurology Radiopharma Product Leader

Full-TimeUpdated on 10/22/2026Deadline 10/30/26
$193.6k - $290.4k/yr+ Performance-based cash bonus(es) + Long-term incentives
Expert
PharmD, PhD, MD
Remote in USA
Remote
Biology & BiotechRegulatory & Quality (Life Sciences)
No H1B Sponsorship

About the job

Requirements
  • An advanced degree in Life Sciences, Medicine, Pharmacy, Engineering, or a related field (for example, PhD, MD, or PharmD), with strong scientific credibility and strategic orientation.
  • Significant experience in product leadership, including milestone-based product development, launch readiness, and lifecycle management.
  • Deep expertise in neurology, radiopharmaceuticals, and molecular imaging, with strong knowledge of PET and SPECT.
  • Demonstrated ability to shape product and indication strategies in complex, cross-functional global environments.
  • Established relationships in the neurology and neuroimaging community, particularly in Alzheimer’s disease and related PET imaging spaces.
  • Experience working across global markets and influencing diverse stakeholders in a matrixed organization.
  • Experience launching diagnostic or imaging products in the U.S.; neurology-focused experience is strongly preferred.
Responsibilities
  • Define and lead global product strategy for neurology radiopharmaceutical assets, primarily focused on Parkinson’s disease and Alzheimer’s disease.
  • Develop target product profiles based on unmet clinical need, customer insights, and market requirements to inform development strategy and maximize asset value.
  • Build and evolve indication strategies for platform assets, prioritizing opportunities by patient need, scientific rationale, commercial potential, and competitive dynamics.
  • Shape portfolio priorities and business cases to support investment decisions, development sequencing, and long-term value creation across the neurology pipeline.
  • Lead the Integrated Evidence Generation Plan for key assets, prioritizing initiatives that accelerate adoption and demonstrate clinical and economic value.
  • Partner with Medical Affairs, Clinical Development, and Commercial teams to align evidence generation with regulatory, reimbursement, and market adoption objectives.
  • Help define the value narrative for pipeline and in-line assets, including differentiation, clinical utility, and relevance to healthcare systems and treatment pathways.
  • Oversee pre-launch, launch, and post-launch strategy across priority markets, ensuring cross-functional alignment and execution readiness.
  • Identify opportunities for label expansion, new indications, and lifecycle optimization through real-world evidence, customer insights, and market evolution.
  • Support portfolio decisions by assessing trade-offs across indications, geographies, and development pathways.
  • Monitor global market trends, competitive activity, clinical practice developments, and unmet needs to inform strategic decisions and portfolio positioning.
  • Develop business cases for geographic expansion beyond the U.S., including assessment of market attractiveness, reimbursement considerations, clinical development requirements, and launch readiness.
  • Evaluate market maturity and health system readiness to support sequencing and prioritization of expansion opportunities.
  • Partner with Clinical Development to align clinical trial design, endpoints, and evidence plans with product strategy and commercial objectives.
  • Collaborate with Regulatory, Market Access, Medical Affairs, and Commercial teams to develop and execute integrated strategy across the product lifecycle.
  • Work with relevant stakeholders to support integration of PET imaging into neurology care pathways and broader clinical practice.
  • Build and maintain relationships with key opinion leaders, academic experts, and external stakeholders in neurology, neuroimaging, and nuclear medicine.
  • Use external networks and scientific engagement to inform strategy, strengthen market understanding, and support adoption of innovative molecular imaging solutions.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Tuition Reimbursement
  • Relocation Assistance

Company News

Associated Press
Oct 20th, 2026
GE HealthCare launches five-institution global trial of StarGuide GX theranostics SPECT/CT system

GE HealthCare has launched a clinical evaluation program for StarGuide GX, its next-generation digital 4D SPECT/CT system. Five institutions across three continents will take part. They are Hadassah Medical Center and Rambam Health Care Campus in Israel, Mayo Clinic in the US, Oncopole Claudius Regaud in France, and Peking University First Hospital in China. Each will assess image quality, quantitative performance, dynamic imaging, and workflow, and give feedback to guide the system's development. StarGuide GX uses dual-sided cadmium zinc telluride detectors and a dual-collimator design meant to remove manual collimator changes. It also uses NVIDIA RTX accelerated computing for image reconstruction. The system received CE Mark in November 2025 and is on sale in select EU states. Its US Food and Drug Administration 510(k) clearance is pending.

Yahoo Finance
Oct 19th, 2026
GE HealthCare launches LOGIQ Focus ultrasound with AI tools, 26% faster scans

GE HealthCare has launched LOGIQ Focus, a new general imaging ultrasound system in its LOGIQ family. The company announced the product in Chicago on October 19, 2026. The system runs on cSound Architecture and pairs high-definition imaging with AI-enabled tools. One of them, Auto Preset Assistant, detects the anatomy being scanned and activates the matching preset, saving up to five clicks per exam. In a third-party study, 90% of participants rated its image quality as excellent. The system was 26% faster than the predicate system. LOGIQ Focus is 510(k) cleared and CE Marked. GE HealthCare expects it and several other new products to add 1% to 2% to revenue growth, following more than $5 billion in innovation investment since 2023.

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.

PR Newswire
Sep 30th, 2026
AsiaMedic first in ASEAN to deploy GE HealthCare's MR31 deep learning MRI platform

AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.

Associated Press
Sep 22nd, 2026
GE HealthCare raises quarterly dividend 14% to $0.04 per share for Q3 2026

GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.